SARAH CAIN: Open Payments
NPI 1952168098 · AUSTIN, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$447 in 14 payments from 9 companies in 2025. Trend: 2023 $0 · 2024 $290 · 2025 $447
Food & beverage: $447
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 3 | $183 |
| Genmab U.S., Inc. | 2 | $52 |
| KYOWA KIRIN, INC. | 2 | $52 |
| Celgene Corporation | 2 | $39 |
| GlaxoSmithKline, LLC. | 1 | $30 |
| ARRAY BIOPHARMA INC | 1 | $27 |
| Incyte Corporation | 1 | $26 |
| Stemline Therapeutics Inc. | 1 | $19 |
| AstraZeneca Pharmaceuticals LP | 1 | $18 |
Products named: RYBREVANT, TECVAYLI, Epkinly, POTELIGEO, REBLOZYL, JEMPERLI, BRAFTOVI, MONJUVI.
Industry payments across TX — which companies pay providers there.
